Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
== History == Valproic acid was first synthesized in 1882 by Beverly S. Burton as an analogue of valeric acid, found naturally in valerian. Valproic acid is a carboxylic acid, a clear liquid at room temperature. For many decades, its only use was in laboratories as a "metabolically inert" solvent for organic compounds. In 1962, the French researcher Pierre Eymard serendipitously discovered the anticonvulsant properties of valproic acid while using it as a vehicle for a number of other compounds that were being screened for antiseizure activity. He found it prevented pentylenetetrazol-induced convulsions in laboratory rats. It was approved as an antiepileptic drug in 1967 in France and has become the most widely prescribed antiepileptic drug worldwide. Valproic acid has also been used for migraine prophylaxis and bipolar disorder.
=== First Nations relations === In March 2021, Ford publicly accused MPP Sol Mamakwa of "jumping the line" to receive his second dose of a COVID-19 vaccine, despite being eligible to receive it. Mamakwa went to his riding to receive the vaccine as an attempt to prevent vaccine hesitancy amongst his constituents. On Thursday, March 11, 2021, Ford apologised for his remark and later said he "got a little personal" when throwing the accusation at Mamakwa. Mamakwa did not say that he accepted Ford's apology but stated that he appreciated the call from Ford. In September 2021, an Ontario judge issued an injunction on mining in Wiisinin Zaahgi'igan (an area sacred to the Ginoogaming First Nation peoples). The judge ruled that the Ontario government did not consult with the Ginoogaming as is their constitutional duty. Ford's 2024 Reducing Gridlock, Saving you Time Act removed the requirement for future Indigenous consultation for the upcoming Highway 413 in a possible contravention of Ontario's Environmental Assessment Act. In addition, the Indigenous consultation period for the bill was only 30 days, decried by the regional chief as 'too short'. Many Indigenous and environmental advocacy groups opposed his government's Protecting Ontario by Unleashing Our Economy Act, or Bill 5, which gives Ford's cabinet the ability to create special economic zones and exempt companies or projects from having to comply with any provincial law, provincial regulation or municipal bylaw. Ford also apologized for saying that First Nations "keep coming hat in hand" for government money in June 2025.
== Research centres and major projects == The Scar Free Foundation (formerly The Healing Foundation) has co-ordinated research projects in burns, cleft, conflict wounds, and scarring genetics since its inception in 1998. Notable projects include:
Sources: en.wikipedia.org
== Modern hue rendering == True Tyrian purple, like most high-chroma pigments, cannot be accurately rendered on a standard RGB computer monitor. Ancient reports are also not entirely consistent, but these swatches give a rough indication of the likely range in which it appeared: _________ _________ The lower one is the sRGB colour #990024, intended for viewing on an output device with a gamma of 2.2. It is a representation of RHS colour code 66A, which has been equated to "Tyrian red", a term which is often used as a synonym for Tyrian purple.
== History == AOA1 was first described by Aicardi and colleagues in 1988. In 2001, Moreira and colleagues, and Date and colleaguees mapped the gene for AOA1 to 9p13 in Portuguese and Japanese populations.
42 BC to at least early 5th century, Mark Antony (emblem: capricorn) Legio V Macedonica (Macedonian): 43 BC – AD 637, Octavian (emblem: bull) Legio V Alaudae (Larks): 52 BC – AD 70 or 86 (destroyed either during the Batavian rebellion or by the Dacians in first Battle of Tapae), Julius Caesar (emblem: elephant) Legio VI Ferrata (Ironclad): 52 BC – after AD 250, Julius Caesar (emblem: bull, she-wolf and Romulus and Remus); twin legion of Legio VI Victrix Legio VI Victrix (Victorious): 41 BC – after AD 402, Octavian (emblem: bull) Legio VII Claudia Pia Fidelis (loyal and faithful to Claudius): before 58 BC – 44 BC, Julius Caesar; disbanded and re-formed by Octavian Legio VIII Augusta: 59 BC – 46 BC, Julius Caesar, originally named Gallica, disbanded and re-enlisted by Octavian as Legio VIII Augusta, 44 BC – AD 420 Legio IX Hispana (Hispanian): before 58 BC – AD 120-161 Legio X Equestris (Equestrian): before 58 BC – 45 BC, Julius Caesar's personal legion, later renamed as Legio X Gemina Legio X Fretensis (of the sea strait): levied by Octavian in 41/40 BC, recorded to have existed at least until the 410s Legio XI Claudia: 58 BC – 45 BC, Julius Caesar (emblem: Neptune), disbanded, reconstituted by Octavian Legio XII Fulminata (Thunderbolt): 57 BC – AD 45, Julius Caesar, first reconstituted by Lepidus in 43 BC, named by Mark Antony as Legio XII Antiqua (Ancient) Legio XIII Gemina (Twin): 57 BC – 45 BC: Julius Caesar, later (41 BC) reconstituted by Octavian. The legion that crossed the Rubicon with Caesar on his assault on Rome.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.